iBio, Inc. Q3 2025: Revenue $0.22M, Net Loss $2.25M

Ticker: IBIO · Form: 10-Q · Filed: May 2, 2025 · CIK: 1420720

Ibio, Inc. 10-Q Filing Summary
FieldDetail
CompanyIbio, Inc. (IBIO)
Form Type10-Q
Filed DateMay 2, 2025
Risk Levelmedium
Sentimentbearish

Sentiment: bearish

Topics: 10-Q, financials, biotech

TL;DR

iBio's Q3 2025 shows $0.22M revenue, $2.25M net loss. Assets $9.86M, Liabilities $3.71M.

AI Summary

iBio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $9.86 million and total liabilities of $3.71 million. For the three months ended March 31, 2025, iBio reported revenue of $0.22 million and a net loss of $2.25 million.

Why It Matters

This filing provides a snapshot of iBio's financial health and operational performance for the third quarter of fiscal year 2025, impacting investor decisions and market perception.

Risk Assessment

Risk Level: medium — The company reported a net loss, indicating ongoing financial challenges that could pose a risk to its future operations.

Key Numbers

  • $9.86M — Total Assets (As of March 31, 2025)
  • $3.71M — Total Liabilities (As of March 31, 2025)
  • $0.22M — Revenue (For the three months ended March 31, 2025)
  • $2.25M — Net Loss (For the three months ended March 31, 2025)

Key Players & Entities

  • iBio, Inc. (company) — Filer
  • March 31, 2025 (date) — Reporting Period End Date
  • $9.86 million (dollar_amount) — Total Assets
  • $3.71 million (dollar_amount) — Total Liabilities
  • $0.22 million (dollar_amount) — Revenue for the three months ended March 31, 2025
  • $2.25 million (dollar_amount) — Net Loss for the three months ended March 31, 2025

FAQ

What was iBio's total revenue for the nine months ended March 31, 2025?

The filing indicates that for the nine months ended March 31, 2025, iBio reported total revenue of $0.92 million.

What was the net loss for the nine months ended March 31, 2025?

For the nine months ended March 31, 2025, iBio reported a net loss of $9.20 million.

What are the company's total assets as of March 31, 2025?

As of March 31, 2025, iBio reported total assets of $9.86 million.

What are the company's total liabilities as of March 31, 2025?

As of March 31, 2025, iBio reported total liabilities of $3.71 million.

What was the net loss for the three months ended March 31, 2025?

For the three months ended March 31, 2025, iBio reported a net loss of $2.25 million.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 2, 2025 regarding iBio, Inc. (IBIO).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.